UNC Slides adapted from a presentation by Cindy Gay MD UNC Associate Professor Infectious Disease November 13 2020 Increasing Cases in North Carolina Black and Latino populations disproportionately ID: 1040810
Download Presentation The PPT/PDF document "COVID-19 VACCINE TRIALS AT" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
1. COVID-19 VACCINE TRIALS AT UNCSlides adapted from a presentation by:Cindy Gay, MDUNC Associate ProfessorInfectious DiseaseNovember 13, 2020
2. Increasing Cases in North Carolina Black and Latino populations disproportionately affectedhttps://covid19.ncdhhs.gov/dashboard/
3. Cases in Congregate Settings in NChttps://covid19.ncdhhs.gov/dashboard/outbreaks-and-clusters12%8%0.87%Death rate
4. Supported Vaccine Studies
5. Moderna Vaccine trial The COVE Study at UNC
6. Who was in the Study?At high risk for COVID-19Work in high risk jobsLive or work in nursing homesIncluded African Americans 28%, Hispanic/Latino 26%, Native Americans 1% and older adults 13%Those at risk for severe disease:DiabetesHeart diseaseChronic lung diseaseChronic liver diseaseOverweight, BMI >40Included even if you had a pre-existing stable medical conditions that did not need treatment or hospitalization in the last 2-3 months
7. Who was in the Study?ExcludedPeople who had already had COVID-19 People who were sick or had a fever in the past 3 daysWomen who were pregnant/breastfeedingPeople who were immunocompromised
8. Phase 3 – The Cove StudyRandomized, placebo-controlled, stratified, blinded studyIntervention: 2 doses vaccine or placebo at Days 0 and 29Primary Objectives: 1) Safety and reactogenicity of 2 injections 28 days apart2) Efficacy of mRNA-1273 to prevent COVID-19 illnessAlso: prevent infection, severe COVID-19 illness after 1 and 2 doses, deathTarget enrollment: 30,000 participants across >100 US sites completed Oct 23.
9. How mRNA vaccines workmRNA is like a text message. It tells the cell to make a tiny piece of the spike protein unique to COVID-19. This cannot cause an infection.The spike protein causes your body to make antibodies and activates T cellsThe mRNA never enters the cell nucleus or affects the DNAThe cells in your body then dispose of the RNA completely. mRNA vaccines have been used against CMV, human metapneumovirus, and parainfluenza virus type 3, Zika virus, and influenza virus.Currently available under an emergency use authorization
10. COVID-19 vaccine targets the Spike10Cells in Human BodyCoronavirus The coronavirus spike protein attaches to the ACE2 receptor to start infection.Slide credit: Vaccine Research Center, NIAIDSpike ProteinHuman ACE2 ReceptorYou cannot catch COVID-19 from the vaccine and it does not change your DNA
11. Pfizer Side Effects those under age 65
12. Pfizer Side Effects those over age 65
13. HOw do you prepare your residents and staff?ASK-TELL-ASK